

LAURA E. HAPPE

PHARMD, MPH

19905 SANEDYEDGE DRIVE
CORNELIUS, NC 28031
lehappe@gmail.com
727-488-2700
www.laurahappe.com

CAREER PROFILE

Clinical and outcomes research executive with 15+ years of experience in managed care, research, and academia ♦ History of building new functions within large companies ♦ Expertise in organizational strategy, evidence-based value proposition, research design and communication, motivating and inspiring teams ♦ Sitting editor-in-chief of Journal of Managed Care and Specialty Pharmacy

Areas of Expertise:

Anticoagulation
Claims data
Copay accumulators
Epidemiology
Managed care
Medicare
Multiple sclerosis
Opioids
Pharmacoeconomics
Population health
Real world evidence
Vaccines
Value-based care

www.jmcp.org

Humana work samples:

[Opioid Podcast](#)
[Health Affairs Blog](#)
[Research website](#)
[Research library](#)

CURRENT WORK PORTFOLIO

University of Florida | 2019-present

- Director of managed care pharmacy track within Master's degree program in pharmaceutical outcomes and policy
- Instructor of managed care pharmacy courses

Wingate University | Associate Professor Pop. Health | 2018- present

- Lead faculty member designing population health curriculum for nursing, occupational therapy, pharmacy, physician assistant and physical therapy programs
- Instructor of pharmacoeconomics, health care systems and communications within PharmD curriculum

Journal of Managed Care and Specialty Pharmacy | Editor in Chief, Assistant Editor | 2013-present

- Executive leader of peer-reviewed journal published monthly with a circulation of 33,000 and an impact factor of 2.5
- Lead team of assistant, managing, and copy editors, and volunteer editorial advisory board
- Responsible for evaluating the rigor and relevance of submitted articles, making publication decisions based on peer review, and providing strategic direction for the journal

PRIOR EXPERIENCE

Humana, Inc. | Chief Pharmacy Officer | 2017-2018

- Clinical executive for 4th largest pharmacy benefits manager in US and the 7th largest retail pharmacy chain dispensing 400 million 90 day supply prescriptions annually
- Lead the population health and outcomes research team, advancing strategy and enhancing drug contract negotiations

PRIOR EXPERIENCE (CONT.)

- Responsible for government affairs team advocating and influencing CMS policy
- Direct practice community for 700 pharmacists and 1500 pharmacy technicians, with 76% of pharmacists practicing at top of license
- Established and lead enterprise opioid task force – reduced use by ~20%, implemented disposal program, designed OUD strategy
- Established and lead enterprise opioid task force – reduced use by ~20%, implemented disposal program, designed OUD strategy

Humana, Inc. (cont.) | *Director of Research and Publications* | 2014-2017

- Hired by Chief Medical Officer to establish novel peer-reviewed publication program to advance Humana’s strategic initiatives
- Collaborated with over 20 analytic teams across the enterprise to elevate study design for internal decisions and external publishing
- Influenced a company-wide adoption of a culture of research
- Built relationships and collaborations with external partners including: CDC, RWJF, UPenn, & Harvard
- Published 2, 6, 13, 18 papers in years 1 through 4, respectively
- Presented ~30 posters/podiums annually

Presbyterian College School of Pharmacy | *Associate Professor* | 2011-2013

- Founding member of Presbyterian College School of Pharmacy
- Professor: Health Care Systems, Pharmacy Administration I and II, Biostatistics I and II
- Established and led Innovation and Entrepreneurship Program certificate program
- Academy of Managed Care Pharmacy Student Chapter advisor

Xcenda, Amerisource Bergen | *Director, Senior Consultant, Consultant, Fellow* | 2003-2011

- Built managed markets function with payer strategy and value proposition development
- Aided in company growth from boutique firm to >500 associates and acquired by major drug distributor
- Project types included pharmacoeconomic modeling, administrative claims database analyses, advisory boards, qualitative research, disease management programs, and medical writing

Established
[Innovation and
Entrepreneurship
Program](#)

ACADEMIC TRAINING

PharmD	Creighton University Medical Center School of Pharmacy <i>Cum laude</i> Omaha, Nebraska
MPH	Epidemiology, University of South Florida Tampa, Florida
Fellowship	Xcenda Health Outcomes Research and Pharmacoeconomics Palm Harbor, Florida

PROFESSIONAL SERVICE

Repeat Study Scientific Advisory Board, 2017-present

University of Maryland Patient-driven Values in Healthcare Evaluation (PAVE)
Center Stakeholder Advisory Panel, 2017-present

Academy of Managed Care Pharmacy

- AMCP/FMCP Joint Research Committee Member, 2017-present
- Chair of Schools of Pharmacy Relations Committee, 2012-2013
- Vice Chair of Schools of Pharmacy Relations Committee, 2011-2012
 - Schools of Pharmacy Relations Committee Member, 2010-2011
 - Diplomat, 2011-2014

Adjunct Clinical Assistant Professor (Preceptor)

- Palm Beach Atlantic University, 2004-2006
- University of Florida College of Pharmacy, 2003-2006

Pharmacy Licenses:

Arizona
Florida

[Repeat Initiative](#)

PUBLICATIONS

1. Schneeweiss S, Brown J, Rothman K, [Happe LE](#), Arlett P, Dal Pan, G, Goettsch W, Murk W, Wang S. Graphical depiction of longitudinal study designs in healthcare databases. *Ann Intern Med*. In press.
2. Ems D, Murty S, Loy B, Gallagher J, [Happe LE](#), Rogstad TL, Fennel D, Fernandez J. Alternative payment models in medical oncology: Outcomes under partial capitation. *Am Health Drug Benefits*. 2018;7(11):371-378.
3. Lee AN, Johnson R, Lakhani, [Happe LE](#). Outcomes at bariatric surgery centers of excellence and non-designated centers: A retrospective cohort study in a TRICARE population. *Am Surg*. 2018;84(3):410-415.
4. Espinosa CM, Marshall GS, Woods CR, Ma Q, Ems D, Nsiah I, [Happe LE](#), Smith MJ. Missed opportunities for human papillomavirus vaccine initiation in an insured adolescent female population. *J Pediatric Infect Dis Soc*. 2017;6(4):360-5.
5. Powell AC, Mirhadi AJ, Loy BA, [Happe LE](#), Long JW, Kren EM, Gupta AK. Presentation at computed tomography scan of the thorax and first year diagnostic and treatment utilization among patients diagnosed with lung cancer. *PLoS One*. 2017 Jul 14;12(7):e0181319. doi: 10.1371/journal.pone.0181319. eCollection 2017.
6. Beech BM, Cordier T, [Happe LE](#), Trunk L, Haugh GS, Kwong R, Gopal V, Beveridge RA. Does a free office visit affect primary care-seeking behavior? A study of new exchange health plan enrollees in Mississippi. *Am Health Drug Benefits*. 2017;10(2):64-71.
7. Castro Sweet CM, Chiguluri V, Gumpina R, Abbott P, Madero EN, Payne M, [Happe L](#), Matanich R, Renda A, Prewitt T. Outcomes of a digital health program with human coaching for diabetes risk reduction in a Medicare population. *J Aging Health*. 2017; January 24. [Epub ahead of print]
8. Robertson-Cooper H, Neaderhiser B, [Happe LE](#), Beveridge RA. Family physician readiness for value-based payments: Does ownership status matter? *Popl Health Manag*. 2017 Oct;20(5):357-361. doi: 10.1089/pop.2016.0135. Epub 2017 Jan 18.
9. Slabaugh L, Shah M, Zack M, [Happe L](#), Cordier T, Havens E, Davidson E, Miao M, Prewitt T, Jia H. Leveraging health related quality of life in population health management: The case for Healthy Days. *Popul Health Manag*. 2017;20(1):13-22.
10. Beveridge RA, [Happe LE](#), Funk M. The physician-insurer dynamic must shift to successfully implement value-based payments. *Healthc(Amst)*. 2016;4(4):282-284.
11. Loy B, Shkedy C, Powell A, [Happe L](#), Royalty J, Miao M, Smith G, Long J, Gupta A. Do case rates affect physicians' clinical practice in radiation oncology? *PLoS One*. 2016;11(2):e0149449.
12. Lopez A, Long CL, [Happe LE](#), Relish M. Using sequence discovery to target outreach for diabetes medication adherence. *Am J Manag Care*. 2015;21(11):e601-e608.
13. Loy B, Brooks WT, Yang M, [Happe LE](#), Van Gilder T. Longitudinal evaluation of a colorectal cancer screenings measurement model. *J Natl Compr Canc Netw*. 2015;13:624
14. Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, [Happe LE](#), Blalock SJ. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. *Curr Med Res Opin*. 2015;31(2):289-97.

15. Franklin MA, [Happe LE](#), Dillman R, Marshall LZ. Frequency and economic impact of comorbid cardiac conditions with multiple sclerosis. *J Manag Care Spec Pharm*. 2014;20(8):795-9.
16. [Happe LE](#), Holliday E, Young T, Clark D. A systematic literature review of the directional impact of managed care formulary restrictions on patient outcomes. *J Manag Care Pharm*. 2014;20(7):677-84.
17. [Happe LE](#). Choosing the best treatment for multiple sclerosis: Comparative effectiveness, safety, and other factors involved in disease modifying therapy choice. *Am J Manag Care*. 2013;19:S332-S342.
18. [Happe LE](#), Walker D. Pharmacy Students for an Evolving Health Care Delivery System Through the Use of Grey Literature. *Am J Pharm Educ*. 2013;44(7):1-7.
19. Miller R, [Happe LE](#), Meyer K, Spear R. Approaches to the management of agents used for the treatment of multiple sclerosis: Consensus statements from a panel of United States managed care pharmacists and physicians. *J Manag Care Pharm*. 2012;18(1):54-62.
20. Farias-Eisner R, Horblyuk R, Franklin M, Lunacsek O, [Happe L](#). Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery. *CMRO*. 2009;25(5):1081-1087.
21. [Happe LE](#), Rao SV, Horblyuk R, Franklin M, Lunacsek OE, Menditto L. Consequences of major bleeding in hospitalized patients with non-ST segment elevation acute coronary syndromes receiving injectable anticoagulants. *CMRO*. 2009;25(2):413-420.
22. [Happe LE](#), Lunacsek OE, Kruzikas DT, Marshall GS. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population. *Pediatr Infect Dis J*. 2009;28(2):98-101.
23. Shorr AF, Nutescu E, Farrelly E, Horblyuk R, [Happe L](#), Franklin M. Postdischarge oral versus injectable anticoagulation following major orthopedic surgery. *Ann Pharmacother*. 2008;42:1216-1221.
24. Nutescu E, Shorr AF, Farrelly E, Horblyuk R, [Happe L](#), Franklin M. Burden of Deep Vein Thrombosis in the Outpatient Setting Following Major Orthopedic Surgery. *Ann Pharmacother*. 2008;42:1222-1228.
25. Kwong LM, [Happe LE](#), Horblyuk R, Farrelly E. Decreased venous thromboembolism with injectable vs oral anticoagulation following discharge for major orthopaedic surgery. *J Arthroplasty*. 2008 Sep;23(6 Suppl 1):25-30.
26. Comp P, [Happe LE](#), Sarnes MW, Farrelly E. Clinically-Detected Venous Thromboembolism Following Hip Fracture Surgery with Prophylaxis in a Clinical Practice Setting. *Am Journal Orthop*. 2008;37(9)470-475.
27. Shorr A, Sarnes M, Peeples P, Stanford R, [Happe L](#), Farrelly E. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery. *Am J Health Syst Pharm*. 2007 Nov 15;64(22):2349-55.
28. Shorr A, Kwong L, Sarnes M, [Happe L](#), Farrelly E, Mody-Patel N. Venous thromboembolism after orthopedic surgery: Implications of the choice for prophylaxis. *Thromb Res*. 2007. 121(1): 17-24.
29. [Happe L](#), Farrelly E, Stanford RH, Sarnes M. Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following orthopaedic surgeries. *Journal of Thrombosis and Thrombolysis*. 2008;26(2):125-31.

30. Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Russell AR. Use of combination vaccines is associated with improved coverage rates. *Pediatr Infect Dis J* 2007;26: 496–500.
31. Happe LE, Lunacsek OE, Marshall GS, Lewis T, Spencer S. Combination vaccine use and vaccination quality in a managed care population.. *Am J Manag Care*. 2007;13:506-512.
32. Eaddy MT, Druss BG, Sarnes MW, Regan TS, Frankum (Happe) LE. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy--results from a managed care administrative claims database. *J Manag Care Pharm*. 2005;11(2):145-150.
33. Frankum (Happe) LE, Nightengale B, Russo CL, Sarnes MW. Pharmacoeconomic analysis of sequential treatment pathways in the treatment of onychomycosis. *Manag Care Interface*. 2005;18(1):55-63.
34. Sarnes MW, Frankum (Happe) LE. Pharmacoeconomic evaluation of antidepressant therapies. *Manag Care*. 2004;13(suppl 6):34-41.

POSTER/PODIUM PRESENTATIONS

1. Happe LE, Owens C, Martin A, Brown C, Long C. Managed care pharmacists and top of licence practice: Understanding the perceptions, barriers, and readiness. Poster Presentation at: Academy of Managed Care Pharmacy. March 2015. San Diego, CA.
2. Cordier TA, Trunk L, Haugh GS, Happe LE, et al. A Retrospective Investigation into Primary Care Seeking Behavior in Mississippi among Newly Insured Affordable Care Act Exchange Enrollees with a Single National Payer. Poster Presentation at: AcademyHealth. June, 2015; Minneapolis, MN, USA.
3. Happe LE, Marshall LZ, Dickson M, Franklin MA. Frequency and economic impact of comorbid cardiac conditions among hospitalizations of patients with multiple sclerosis. [Poster]. Presented at the International Society of Pharmacoeconomics and Outcomes Research 18th Annual International Meeting. May 2013. New Orleans, LA.
4. Rosenman MB, Baker L, Jing Y, Makenbaeva D, Meissner B, Simon TA, Wiederkehr D, Happe L, Deitelzweig S. Why warfarin is not used for stroke prevention in atrial fibrillation: A detailed review of electronic medical charts. Poster Presentation. Presented at the International Stroke Conference. February 1-3, 2012. New Orleans, LA.
5. Null DM, D'Souza, O'Day KB, Happe LE. The economic burden of bronchopulmonary dysplasia during the first two years of life. [Poster]. Presented at European Academy of Pediatrics. October 24-28, 2008. Nice, France.
6. Null DM, Lunacsek OE, O'Day KB, Happe LE. Cost of bronchopulmonary dysplasia during the birth hospitalization. [Poster]. Presented at American Academy of Pediatrics. October 11-14, 2008. Boston, MA.
7. Kwong L, Horblyuk R, Happe LE, Farrelly E. Thrombotic and hemorrhagic outcomes and surgical site infection rates in unit compartmental knee arthroplasty vs. total knee arthroplasty. [Poster]. Presented at 9th European Federation of National Associations of Orthopaedics and Traumatology (EFFORT) Congress. May 29- June 1, 2008. Nice, France.

8. Horblyuk R, Lunacsek OE, Happe LE. Venous thromboembolism and bleed rates among antithrombotic agents in elderly orthopedic patients. [Poster]. Presented at American Geriatrics Society. April 30- May 4, 2008. Washington, D.C.
9. Stanford R., Happe L, Farrelly E., Eaddy M. Costs and Outcomes in Orthopaedic Patients Who Received Thromboprophylaxis with Dalteparin, Enoxaparin, Fondaparinux or Unfractionated Heparin. [Poster]. Presented at Academy of Managed Care Pharmacy 2007 Conference. April 11-14, 2007. San Diego, CA.
10. Kwong L, Happe L, Horblyuk R, Farrelly E. Outcomes of post-hospital injectable vs. oral anticoagulation following major orthopaedic surgery (MOS). [Podium]. Presented at the American Association of Hip and Knee Surgeons Annual Meeting. November 2-4, 2007. Dallas, TX.
11. Stanford R, Mody-Patel N, Happe L, Farrelly E, Sarnes M. Major bleed and all-cause inpatient mortality between anticoagulants used post-orthopedic surgery in a clinical setting. [Podium]. Presented at the American College of Clinical Pharmacy, October 26-29, 2006. St. Louis, MO.
12. Shorr A, Kwong L, Patel NM, Stanford R, Sarnes M, Happe L. Venous Thromboembolism Following Hip Fracture Surgery: Outcomes as a Function of Pharmacologic Prophylaxis Regimen. [Poster]. Presented at the American College of Chest Physicians, October 21-26, 2006. Salt Lake City, UT.
13. Shorr A, Horblyuk R, Farrelly E, Happe L. Outcomes of post-discharge anticoagulation using oral versus injectable agents following major orthopaedic surgery. [Podium]. Presented at American College of Chest Physicians. October 20-25, 2007. Chicago, IL.
14. Shorr A, Horblyuk R, Happe L, Farrelly E. Cost of post-discharge anticoagulation using oral versus injectable agents following major orthopaedic surgery (MOS). [Poster]. Presented at Academy of Managed Care Pharmacy 2007 Educational Conference. October 4-11, 2007. Boston, MA.
15. Patel NM, Happe L, Farrelly E, Sarnes M. Single source cost estimates for events across various conditions requiring thromboembolic prophylaxis and treatment. [Poster]. Presented at the International Society for Pharmacoeconomics and Outcomes Research, May 20-24, 2006. Philadelphia, PA.
16. Sarnes M, Patel NM, Happe L, Farrelly E. Occurrence of thrombocytopenia after orthopedic surgeries in patients treated with fondaparinux, dalteparin, enoxaparin or unfractionated heparin. [podium]. Presented at the International Society for Pharmacoeconomics and Outcomes Research, May 20-24, 2006. Philadelphia, PA.
17. Sarnes M, Shorr A, Happe L, Farrelly E, Higashi M. Major bleed rates after orthopedic surgeries in patients prophylaxed with unfractionated heparin, enoxaparin, dalteparin or fondaparinux. [Poster]. Presented at the Society of Hospital Medicine. May 4-6, 2006. Washington, DC.
18. Shorr A, Sarnes M, Happe L, Farrelly E, Higashi M. Venous thromboembolism rates after hip fracture surgery in patients treated with unfractionated heparin, enoxaparin, dalteparin or fondaparinux. [Poster]. Presented at the Society of Hospital Medicine. May 4-6, 2006. Washington, DC.
19. Patel NM, Happe L, Sarnes M, Farrelly E. Costs of venous thromboembolism and major bleeds in patients treated with fondaparinux, enoxaparin, or unfractionated heparin. [Poster]. Presented at 3rd Annual Make a Difference: Updates in Orthopaedic Surgery, Orthobiologics and Musculoskeletal Therapeutics. April 20-23, 2006. Marco Island, FL.
20. Sarnes M, Shorr A, Higashi M, Happe L, Farrelly E. Diagnosed venous thromboembolism rates after orthopaedic surgeries in patients treated with unfractionated heparin, enoxaparin, dalteparin, or

fondaparinux. [Poster]. Presented at the American College of Clinical Pharmacy. April 9-12, 2006. Monterrey, CA.

21. Marshall GS, Happe LE, Russell, A. Coverage rates among children receiving combination versus component vaccines in a state Medicaid population. Presented at the National Immunization Conference. March 6-9, 2006. Atlanta, GA.
22. Marshall GS, Happe LE, Russell, A. Impact of first-year DTaP doses on the timeliness of the fourth dose of DTaP among children in a state Medicaid population. Presented at the National Immunization Conference. March 6-9, 2006. Atlanta, GA.
23. Marshall GS, Happe LE, Russell, A. Timeliness of childhood immunizations in a state Medicaid population. Presented at the National Immunization Conference. March 6-9, 2006. Atlanta, GA.
24. Frankum (Happe) LE, Nightengale B, Russo CL, Sarnes M. Pharmacoeconomic analysis of antimycotic agents in the treatment of onychomycosis. [Poster]. Presented at: Academy of Managed Care Pharmacy's 16th Annual Meeting. March 31-April 3, 2004, San Francisco, CA.